Britannia Life Sciences Inc.
BLAB
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -67.63% | -- | -- | 40.21% | -107.57% |
| Total Depreciation and Amortization | -1.77% | -- | -- | 1.77% | 5.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 29.96% | -- | -- | -294.97% | 100.54% |
| Change in Net Operating Assets | 71.99% | -- | -- | 100.39% | -550.88% |
| Cash from Operations | -37.49% | -- | -- | 62.96% | 57.32% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -1,908.97% | -102.45% |
| Cash from Investing | -- | -- | -- | -1,908.97% | -102.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -0.41% | -- | -- | -1.68% | 97.12% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 561.36% | -- | -- | -1.85% | 88.18% |
| Foreign Exchange rate Adjustments | 850.00% | -- | -- | 179.07% | 56.12% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,189.81% | -- | -- | -225.80% | -125.89% |